Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of HDG1901 vs Ozempic in Healthy Subjects
NCT06634927Phase 1Completed
- Sponsor
- Huadong Medicine
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Recombinant polypeptide, Biosimilar, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide biosimilar (HDG1901) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huadong Medicine. Primary endpoints: Area under the concentration-time curve from time zero to infinity up to 840 hours, Area under the concentration-time curve from time zero to the last measurable concentration up to 840 hours and 1 more. Started Sep 2024; status: completed.
02
Drugs
semaglutide biosimilar (HDG1901)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06634927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634927.